SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NTEG- Bloodless Glucose Monitor

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Stratajema who wrote (24)9/14/1997 12:32:00 PM
From: Tevyah   of 176
 
Stratajema: My interpretation of the announcement appointing Richard Mussman VP of R&D was somewhat different. It seems that his primary responsibility is the identification of technology that will lead into FUTURE products and income for Integ. Integ obviously is keenly aware that right now they are a one product company and are therefor seeking avenues of diversification. I can only assume that this man, who must have a better view of the situation with LifeGuide than I do, would not have made a career move if he felt unsure about the future of Integ, ie the LifeGuide meter. In the announcement, Frank Soloman said ``Integ is evolving as a company and, as we draw near to completing the development process on our first product, we need to look ahead. ...''
I think that this is all very upbeat and not indicative of any insurmountable remaining problems with the LifeGuide design. Hopefully we will have news of a design freeze sooner than later. Your guess is as good as mine!

Ken

Here is a repost of the annoncement:

Wednesday July 2 5:23 PM EDT

Company Press Release

Source: Integ Incorporated

Integ Strengthens Its Product Development Capabilities

ST. PAUL, July 2 /PRNewswire/ -- Integ Incorporated (Nasdaq:NTEG) today announced that Robert H. Dodge, Ph.D., who has been serving as the company's vice president, research and development, will assume the position of chief scientific officer, with responsibility for dvanced technology identification and assessment and product concept development. Richard F. Mussmann will join Integ and take on the title of vice president, research and development, with overall responsibility for the new product development programs of the company.

Mussmann most recently served as product management vice president of Telogy Networks. From 1993 to 1995, he was group director, new product development for Ethicon Endo-surgery, where he was responsible for the successful development and launch of 10 new products while reducing product costs and shortening the new product development cycle time. Prior to joining Ethicon Endo-surgery, he was with Boehringer Mannheim Corporation, where he worked on the development of a number of new products, including the Advantage(R) Blood Glucose Monitor. Mussmann also held various engineering and engineering management positions at AT&T Bell Laboratories.

Frank Solomon, Integ's President and CEO, said, ``Integ is evolving as a company and, as we draw near to completing the development process on our first product, we need to look ahead. Our future success will depend on our ability to continue the flow of innovative products. We need both highly skilled and experienced scientific leadership that will generate those ideas and seasoned engineering leadership to turn those ideas into reality.

``The addition of Rich to our team allows Bob to continue to concentrate his scientific creativity on the identification and assessment of emerging technologies and the generation of innovative product concepts by applying those technologies. Rich contributes extensive experience in project management, product integration and product development teams to assure that those concepts are developed and delivered to the market in a cost-effective and timely manner.''

Integ Incorporated is developing the LifeGuide System, a hand-held glucose monitoring product for use by people with diabetes. The LifeGuide System will allow people with diabetes to frequently self-monitor their glucose levels without repeatedly enduring the pain of lancing their fingers and the need to draw blood, thus allowing them to manage their disease more effectively and conveniently.

SOURCE: Integ Incorporated
Contact: John R. Brintnall of Integ, Inc., 612-639-8816, or E-mail: john.brintnall@integ-inc.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext